Drug intelligence / Profile preview

inactivated COVID-19 vaccine + Ad5-nCoV

Development stage
Unknown
Lead developer
CanSino Biologics
Modality
Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration
Intramuscular, Inhalation
01

Overview

This is a combination approach using an inactivated COVID-19 vaccine followed by an Ad5-nCoV booster. Ad5-nCoV (also known as Convidecia) is a recombinant adenovirus type-5 vector-based COVID-19 vaccine developed by CanSino Biologics. The combination approach has been studied for its efficacy in providing enhanced immune response compared to using either vaccine alone. Ad5-nCoV as a single dose induces both humoral and cellular immune responses against SARS-CoV-2, with clinical trials showing 58% efficacy against symptomatic disease and 92% efficacy against severe COVID-19.

02

Targets

RBD (SARS-CoV-2 spike receptor-binding domain)

Beyond the preview

Go deeper on inactivated COVID-19 vaccine + Ad5-nCoV.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on inactivated COVID-19 vaccine + Ad5-nCoV.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call